NEW YORK (GenomeWeb) – Thermo Fisher Scientific has launched a program by which it will collaborate with partners to develop its next-generation sequencing-based Oncomine portfolio of products into clinical tests that can be used as companion diagnostics. The Institute of Medical Genetics and Pathology at University Hospital Basel, Switzerland will be the first partner in the initiative, dubbed the Next Generation Companion Dx Center of Excellence Program.
Thermo Fisher and the University Hospital Basel will collaborate on developing and refining Thermo's Oncomine NGS products for companion diagnostics. In addition, as part of the agreement, the organizations will form partnerships with biopharma groups to launch oncology and immune-oncology trials.
"Through this agreement, we are confident that together we will make great strides to accelerate clinical trial enrollments and develop novel solutions that will benefit hospitals and the patients they serve in the future," Markus Tolnay, who manages the Institute of Medical Genetics and Pathology, said in a statement.